# PT 141 dosage & reconstitution (10 mg vial)

PT 141 dosage: calculations for a 10 mg vial use the same amounts described in the literature. Adding 2 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 10 mg PT 141
- **Final volume:** 2 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (2 mL = ~5 mg/mL)

| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Weeks 1–8 | 500 mcg | 10 units (0.10 mL) |
| Weeks 9–12 | 1 mg (1000 mcg) | 20 units (0.20 mL) |
| Weeks 13–16 | 1.5 mg (1500 mcg) | 30 units (0.30 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

> In the source the route is subcutaneous (abdomen or thigh); no more than one injection per day is described.

### Reconstitution Steps

1. Draw 2 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 100 injections |
| 5 | 0.05 mL | 250 mcg | 40 injections |
| 10 | 0.10 mL | 500 mcg | 20 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 10 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 6 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 4 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 2 injections |

## Supplies Needed

**PT 141 vials (10 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 6 vials (56 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 19 vials (182 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 12 mL total (2 mL per vial) → 4 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 38 mL total (2 mL per vial) → 13 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

PT-141 (Bremelanotide) is a cyclic synthetic heptapeptide (MW: 1025.2 Da) derived from α-MSH (melanocyte-stimulating hormone), developed as a selective agonist of the MC3R and MC4R melanocortin receptors. Unlike its predecessors (Melanotan I/II), PT-141 exhibits optimized selectivity for applications related to sexual function and arousal, with an improved side-effect profile. Molecular Structure: Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH Cyclization: Asp-Lys lactam bridge (conformational stability) Modifications Nle (Norleucine) position 4: prevents oxidation vs Met D-Phenylalanine position 7: proteolytic degradation resistance N-terminal acetylation: exopeptidase protection Selectivity: MC3R/MC4R > MC1R (less pigmentation effect vs. Melanotan II) Melanocortin System and Receptors The melanocortin system comprises 5 receptor subtypes (MC1R-MC5R), each with specific tissue distribution and functions: Receptor Main Distribution Functions PT-141 Affinity MC1R Melanocytes, immune Pigmentation, anti-inflammatory Low-Moderate MC2R Adrenal cortex Steroidogenesis (ACTH) Very Low MC3R SNC (hypothalamus, limbic), peripheral Energy homeostasis, sexual behavior High MC4R SNC…

## Research FAQ

**PT-141 vs. PDE5 Inhibitors (Sildenafil, Tadalafil)?** R: Mechanisms and different applications:
**Why is nausea such a common side effect?** R: MC4R activation of the area postrema:
**Q: What is the documented pharmacokinetic window in the studies?** R: 30-90 minute window:
**Tachyphylaxis or tolerance with chronic use?** R: Limited tolerance:
**Significant drug interactions?** R: Favorable interactions profile:
**P: Differences Melanotan II vs PT-141?** R: PT-141 is an enhanced derivative:
**What do studies in postmenopausal models/populations document?** R: Reported findings:
**Required monitoring for prolonged studies?** Blood pressure Baseline, weeks 2, 4, 8, every 8 weeks Transitory increase of 10-15 mmHg systolic post-dose (monitor)

## References

1. Ficha técnica de bremelanotida (Vyleesi), FDA
2. Kingsberg SA, et al. (2019) “Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials” – Obstetrics and Gynecology 134(5):899-908. [PubMed: 31599832]
3. Portman DJ, et al. (2020) “Continued efficacy and safety of bremelanotide for hypoactive sexual desire disorder” – J Womens Health 29(6):861-869. [PubMed: 31895612]
4. Wessells H, et al. (2000) “Melanocortin receptor agonists, penile erection, and sexual motivation” – Ann NY Acad Sci 897:349-357. [PubMed: 10676462]
5. Diamond LE, et al. (2004) “An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141)” – J Sex Med 3(4):628-638. [PubMed: 16839318]
6. Pfaus JG, et al. (2004) “Facilitation of sexual behavior in the male rat by a melanocortin agonist” – Hormones and Behavior 46(4):431-436. [PubMed: 15465528]
7. Clayton AH, et al. (2016) “Bremelanotide for female sexual dysfunctions in premenopausal women” – J Sex Med 13(9):1506-1513. [PubMed: 27671968]
8. Molinoff PB, et al. (2003) “PT-141: A melanocortin agonist for the treatment of sexual dysfunction” – Ann NY Acad Sci 994:96-102. [PubMed: 12851304]

---
Source: https://protocolopeptidos.com/en/compuestos/pt-141-10mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.